Xiamen Innobiomax Biotechnology

Innobiomax is a clinical-stage biotechnology company headquartered in Xiamen, China, focused on the development of next-generation mRNA vaccines and therapeutics. The company utilizes a proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platform to create treatments for infectious diseases and oncology. Its lead program, IBX-2101, is an mRNA vaccine candidate for COVID-19 that has entered clinical evaluation. Beyond infectious diseases, Innobiomax is advancing a pipeline of personalized cancer vaccines and protein replacement therapies. The company is supported by a strong syndicate of investors, including GL Ventures and Matrix Partners China, and aims to establish a fully integrated mRNA drug development and manufacturing capability.